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Abstract 25 
Objectives: An increasing number of severe-profoundly deaf adult unilateral cochlear implant 26 
(CI) users receive bimodal stimulation; that is, they use a conventional acoustic hearing aid 27 
(HA) in their non-implanted ear. The combination of electric and contralateral acoustic hearing 28 
provides additional benefits to hearing and also to general health-related quality of life 29 
compared to unilateral CI use. Bilateral CI is a treatment alternative to both unilateral CI and 30 
bimodal stimulation in some healthcare systems. The objective of this study was to conduct an 31 
economic evaluation of bimodal stimulation compared to other management options for adults 32 
with bilateral severe to profound deafness. 33 
Design: The economic evaluation took the form of a cost-utility analysis and compared 34 
bimodal stimulation (CI+HA) to two treatment alternatives: unilateral and bilateral CI. The 35 
analysis used a public healthcare system perspective based on data from the United Kingdom 36 
(UK) and the United States (US). Costs and health benefits were identified for both alternatives 37 
and estimated across a patient’s lifetime using Markov state transition models. Utilities were 38 
based on Health Utilities Index (HUI3) estimates and health outcomes were expressed in 39 
Quality Adjusted Life Years (QALYs). The results were presented using the Incremental Cost-40 
Effectiveness Ratio (ICER) and the Net Monetary Benefit approach to determine the cost-41 
effectiveness of bimodal stimulation. Probabilistic sensitivity analyses explored the degree of 42 
overall uncertainty using Monte Carlo simulation. Deterministic sensitivity analyses and 43 
Analysis of Covariance identified parameters to which the model was most sensitive; i.e. whose 44 
values had a strong influence on the intervention that was determined to be most cost-effective. 45 
A Value Of Information analysis was performed to determine the potential value to be gained 46 
from additional research on bimodal stimulation. 47 
Results: The base case model showed that bimodal stimulation was the most cost-effective 48 
treatment option with a decision certainty of 72% and 67% in the UK and US, respectively. 49 
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Despite producing more QALYs than either unilateral CI or bimodal stimulation, bilateral CI 50 
was found not to be cost-effective because it was associated with excessive costs. Compared 51 
to unilateral CI, the increased costs of bimodal stimulation were outweighed by the gain in 52 
quality of life. Bimodal stimulation was found to cost an extra £174 per person in the UK ($937 53 
in the US) and yielded an additional 0.114 QALYs compared to unilateral CI, resulting in an 54 
ICER of £1,521 per QALY gained in the UK ($8,192/QALY in the US). The most influential 55 
variable was the utility gained from the simultaneous use of both devices (CI+HA) compared 56 
to Unilateral CI. The value of further research was £4,383,922 at £20,000/QALY ($86,955,460 57 
at $50,000/QALY in the US). 58 
Conclusions: This study provides evidence of the most cost-effective treatment alternative for 59 
adults with bilateral severe to profound deafness from publicly-funded healthcare perspectives 60 
of the UK and US. Bimodal stimulation was found to be more cost-effective than unilateral 61 
and bilateral CI across a wide range of willingness-to-pay thresholds. If there is scope for future 62 
research, conducting interventional designs to obtain utilities for bimodal stimulation 63 
compared to unilateral CI would reduce decision uncertainty considerably. 64 
  65 
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INTRODUCTION 66 
Cochlear Implants (CI) were formerly considered to be suitable for severe to profoundly deaf 67 
patients who could not benefit from acoustic amplification via conventional hearing aids (Tyler 68 
et al. 2002; Ching et al. 2004). In recent years, technology development and enhanced patient 69 
outcomes have prompted relaxations in the audiometric criteria for cochlear implantation 70 
(Neuman & Svirsky 2013; Siburt & Holmes 2015) and there is a growing population of 71 
unilateral CI users with severe to profound deafness that have residual hearing in the non-72 
implanted ear (Potts et al. 2009; Dorman & Gifford 2010). Current evidence suggests that these 73 
patients can now benefit from acoustic amplification in that ear and should therefore be 74 
managed by combining the electric stimulation from their implant with acoustic stimulation 75 
from a hearing aid (HA) fitted to the contralateral ear (Ching 2006; Scherf & Arnold 2014). 76 
The concurrent use of both hearing devices (CI+HA) is variably referred to as ‘bimodal 77 
stimulation’, ‘bimodal aiding’, or ‘electric and contralateral acoustic stimulation’ (Crew et al. 78 
2015) and can offer important functional advantages compared to CI use alone in at least some 79 
patients (Siburt & Holmes 2015). 80 
There is a large amount of variability in estimates of the prevalence of bimodal stimulation 81 
among adult CI recipients. Most studies report bimodal rates of only 10-32% (Syms et al. 2002; 82 
Tyler et al. 2002; Fitzpatrick et al. 2009; Yamaguchi & Goffi-Gomez 2013; Scherf & Arnold, 83 
2014; Devocht et al. 2015). However, there is a growing population of CI recipients with usable 84 
residual hearing in the contralateral ear due to changes in candidacy criteria over time (Ching 85 
2005), and more patients may now benefit from using a hearing aid in their non-implanted ear 86 
than ever before (Fielden & Kitterick 2016; Neuman et al. 2017). A recent UK study suggested 87 
that the proportion of patients aided bimodally since 2009 may be as high as 48% (Fielden et 88 
al. 2016a). 89 
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Studies have suggested that bimodal stimulation significantly improves outcomes compared to 90 
unilateral cochlear implant use alone in the domains of speech recognition and sound 91 
localization (Potts et al. 2009; Crew et al. 2015), perception of music (Crew et al. 2015), sound 92 
quality (Morera et al. 2012), quality of life (Farinetti et al. 2015), auditory stimulation (Zhang 93 
et al. 2010; Farinetti et al. 2015) and functioning in real life environments (Ching et al. 2004). 94 
Improvements in patients’ hearing ability as a result of bimodal stimulation have been noted in 95 
both quiet and noisy conditions (Harris & Hay-McCutcheon 2010; Farinetti et al. 2015). 96 
Despite this evidence for the potential clinical effectiveness of bimodal stimulation, not every 97 
patient will receive all of these benefits from the use of a contralateral HA. Evidence suggests 98 
that the perceived health benefits of bimodal stimulation may vary due to sub-optimally fitted 99 
hearing aids (Harris & MccCutcheon 2010). Yehudai et al. (2013) also reported that HAs were 100 
found to be malfunctioning in a high proportion of bimodal recipients (81%) and Ching et al. 101 
(2004) observed some level of degradation in speech perception with contralateral HA use. 102 
Malfunction of the HA or the interference that it can cause between the two devices is reported 103 
to be the main reason why many bimodal recipients discontinue use of acoustic amplification 104 
in their non-implanted ear post-implantation (Fitzpatrick & Leblanc 2010; Scherf & Arnold 105 
2014; Fielden & Kitterick 2016). 106 
The decision faced by policy makers is whether managing adults with severe to profound 107 
binaural hearing loss with bimodal stimulation is the most cost-effective option compared to 108 
unilateral or bilateral CI; that is, do the additional health benefits that bimodal stimulation 109 
generates justify the additional costs involved in its provision compared to the other available 110 
alternatives. While the cost-effectiveness of unilateral cochlear implantation compared with 111 
non-surgical management (i.e. HAs) in adults has been reported in many studies (United 112 
Kingdom CI Study Group 2004; Bond et al. 2009; Turchetti et al. 2011), such studies have not 113 
assessed bimodal stimulation as a distinct treatment alternative. For example, Bond et al. 114 
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(2009) conducted an economic evaluation that compared unilateral cochlear implantation 115 
(assuming 70% of individuals used an acoustic hearing aid in their contralateral ear) to 116 
conventional best practice (some patients used HAs and some did not). Although they did 117 
account for the cost of the contralateral HA (£100 on average) and its replacement over time 118 
(every 5 years), they were unable to identify reliable published estimates of the health benefits 119 
(‘utility gain’) from bimodal stimulation and therefore only included the incurred HA costs in 120 
their model. 121 
Goman (2014) assessed the minimum utility gain required for bimodal stimulation to be cost-122 
effective compared to a unilateral CI in adults. The study considered the additional costs 123 
associated with bimodal stimulation including hearing aid appointments (assessment, fitting 124 
etc.) and rehabilitation (aftercare, repairs etc.). The study explored four different scenarios 125 
varying the assumptions around the frequency of the hearing aid replacement and the 126 
percentage of patients receiving rehabilitation.  The author estimated a minimum required 127 
utility gain of between 0.0022 and 0.0109 (depending on included costs) for bimodal 128 
stimulation to be cost-effective at a willingness-to-pay (WTP) threshold of £20,000 per 129 
Quality-Adjusted Life Year (QALY). These estimates represent the best-available evidence for 130 
whether bimodal stimulation may be a cost-effective alternative to unilateral and bilateral CI. 131 
There is an outstanding need to assess the cost-effectiveness of bimodal stimulation compared 132 
to alternative management options. The key methodological issues to overcome are: (a) the 133 
collection of information on the size of the health benefits from a more representative sample 134 
of bimodally-aided, unilateral and bilateral cochlear implant users; and (b) obtaining such data 135 
from a larger population than studied previously. Variability across clinical services in terms 136 
of the fitting and management of hearings aids create the necessity to adjust the economic 137 
evaluation to account for considerable differences across services in terms of both the costs 138 
incurred and the benefits gained (Fielden & Kitterick 2016). The objectives of this study were 139 
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therefore to: (i) conduct a cost-utility analysis of bimodal stimulation compared to unilateral 140 
and bilateral cochlear implantation; (ii) explore how small changes in the health benefits 141 
associated with bimodal stimulation could impact the conclusions of the economic assessment; 142 
and (iii) assess how sensitive the results are to assumptions around how long severe to 143 
profoundly deaf adults will continue to use a contralateral HA after they receive their CI.  144 
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MATERIALS AND METHODS 145 
Ethical Approval 146 
This research was granted ethical approval by the Office for Research Ethics Committees 147 
Northern Ireland (ORECNI, REC reference 15/NI/0054). The research followed the principles 148 
of the Declaration of Helsinki. 149 
 150 
Population 151 
The population under consideration were male and female adults with bilateral severe to 152 
profound deafness which, in the UK, are defined as having pure-tone average thresholds >90 153 
dB HL at 2 and 4 kHz. The study considered the mean age for implantation to be 50 years, 154 
which is consistent with other economic evaluations and assessments of CI provision in the 155 
UK (United Kingdom CI Study Group 2004; Bond et al. 2009; Goman 2014). Our analysis 156 
extrapolated costs and health benefits over a lifetime horizon to reflect the intended duration 157 
of CI use. 158 
 159 
Perspective 160 
The economic evaluation was assessed from a Public Healthcare Service (PHS) perspective to 161 
determine the treatment alternative that maximises health benefits within a limited budget. The 162 
treatment alternatives considered were unilateral cochlear implantation (CI), bimodal 163 
stimulation (CI+HA) and simultaneous bilateral cochlear implantation (CI+CI). In our primary 164 
analysis we used an NHS and PSS perspective (National Health Service and Personal Social 165 
Services), which is United Kingdom (UK) centred. We also conducted a secondary analysis 166 
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using information from the United States (US) that accounted for differences in treatment and 167 
hearing device costs between the two countries. 168 
 169 
Model Description  170 
A decision analytic model was constructed and was based on a decision tree (Fig. 1) and 171 
Markov models using the cohort simulation approach, which follows a cohort of patients as a 172 
whole through each of the possible model states over time. The structure of the model was 173 
based on the clinical pathway that patients commonly follow after unilateral cochlear 174 
implantation in the UK (Bond et al. 2009; NICE 2013). 175 
All patients were first assessed for cochlear implant candidacy and a proportion were assumed 176 
to be ineligible for implantation. Although the modelling of those patients who are not eligible 177 
for implantation is identical across all the treatment alternatives considered in the current study, 178 
their inclusion in the model is necessary as the proportion of patients in a population who can 179 
access a treatment can affect how cost effective it is. 180 
All patients eligible for CI underwent surgery to implant the electrode array (‘internal 181 
component’). These patients then entered a three-state Markov model (Fig. 2) including one 182 
which denotes the use of CI(s) and two absorbent states (i.e. states from which they could not 183 
return to being CI users) representing the non-use of CI(s) and death. Adults in the state 184 
denoting use of CI(s) subsequently entered a second Markov model comprised of four states 185 
that described the success of implantation surgery and function of the device. 186 
The structure of the model was identical for all three treatment options but the model for 187 
bilateral CI assumed patients were implanted simultaneously in both ears and thus included the 188 
cost of two cochlear implants but one surgery. The model for bimodal stimulation accounted 189 
for extra costs and benefits from the additional use of the contralateral HA over unilateral CI 190 
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but also assumed that not all patients will be willing or able to use a contralateral HA. The 191 
proportion of bimodal users was taken from a large-scale cross-sectional UK survey of 359 192 
unilateral cochlear implant recipients that reported a percentage of contralateral HA use of 193 
45.4% (Fielden et al. 2016a, 2017). 194 
The ‘working’ state assumed that the fitted CI(s) was functioning and there were no adverse 195 
effects. It was assumed that all patients experiencing a failure of the sound processor (external 196 
failure) needed a replacement processor. In the case of an internal failure or a major 197 
complication, patients were assumed to require an operation for re-implantation, while a 198 
proportion of those patients would have the implantable component extracted. For bilateral CI, 199 
it was assumed that those who required an extraction continued as unilateral CI users with 200 
associated benefits gained and costs incurred. The non-use state reflected the results of CI 201 
extraction in the case of unilateral CI users and also voluntary permanent non-use. 202 
The patients who were ineligible for CI entered a two-state Markov model with states ‘alive’ 203 
and ‘death’. The alive state represented the non-surgical management of severe to profound 204 
deafness in which a proportion of adults were assumed to benefit from (and therefore use) HAs. 205 
Of those, a proportion were assumed to use two HAs and the remainder a unilateral HA (Bond 206 
et al. 2009). The death state was an absorbent state that represented death due to natural causes 207 
(ONS, 2017). 208 
A discount rate of 3.5% was applied for both costs and health outcomes, based on the HM 209 
Treasury UK (HMS Treasury 2009; NICE 2013). A willingness-to-pay threshold of 210 
£20,000/QALY and $50,000/QALY was used for the UK and US analysis, respectively (NICE 211 
2013; Claxton et al. 2015). A cycle length of 6 months was chosen to illustrate the complexity 212 
of events the first two years after cochlear implantation. The analysis was conducted in 213 
Microsoft Excel 2016. 214 
 215 
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Parameter Values 216 
Transition Probabilities 217 
The probabilities used in the model are listed in Table 1. The probabilities related to cochlear 218 
implantation were obtained from the most up to date economic model of unilateral cochlear 219 
implantation in adults in the UK (United Kingdom Cochlear Implant Study Group 2004; Bond 220 
et al. 2009). The probabilities of external failure and major complications (from year 2 221 
onwards) were assumed to be constant over time, whereas the probability of internal failure 222 
was assumed to be time dependent. To estimate the annual probability of internal failure, 223 
survival curves were generated using the latest Cumulative Survival Percentage (CSP) data 224 
available from a major manufacturer of CIs (Cochlear Ltd. 2016) (see Supplemental Digital 225 
Content 1, which demonstrates the survival curves and best model fits). 226 
Utilities 227 
A postal survey of unilateral CI users in the UK was conducted to determine the ‘utility 228 
weights’ for unilateral CI and bimodal stimulation. Utility weights were estimated by assessing 229 
the self-reported Health-Related Quality of Life (HRQoL) of adult CI users by administering 230 
the Heath Utilities Index Mark 3 (HUI3) instrument (Feeny et al. 2002), a preference-based 231 
measure of health that has been found to be sensitive to interventions that restore hearing (Yang 232 
et al. 2013). The questionnaire was open to all adult unilateral CI users managed by two large 233 
clinical services in the UK who met the following inclusion criteria: (i) they must be at least 234 
18 years of age; (ii) they must have received their CI in the UK; (iii) they must have been 235 
implanted unilaterally. Questionnaires were completed on paper, responses were anonymous, 236 
and no identifying personal information was requested. 237 
A total of 91 patients were confirmed to be eligible and completed the HUI3 questionnaire: 31 238 
bimodal users and 60 unilateral CI users. Bimodal users were defined as those who not only 239 
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reported using a contralateral HA but using it at the same time as their CI. The incremental 240 
utility gain associated with bimodal stimulation was evaluated by comparing the utility weights 241 
of the bimodal group to the unilateral CI group using non-parametric analyses (Mann Whitney 242 
U test) after accounting for differences in the time since implantation. Bias-corrected 243 
confidence intervals for the mean utility weights for the unilateral and bimodal groups were 244 
computed using bootstrapping (Davison & Hinkley, 1997).  245 
Four studies were relevant for estimating the utility of bilateral CI. Summerfield et al. (2006) 246 
reported a utility increment of 0.031 compared to unilateral CI based on the results from a 247 
randomized controlled trial, which was the same incremental value found in an earlier study 248 
that estimated utility values using a scenario-based approach (Summerfield et al., 2002). 249 
Kuthubutheen et al (2016) reported an average utility increment of 0.035 when comparing the 250 
values associated with health state descriptions of bilateral with unilateral CI by patients and 251 
healthcare professionals. Finally, Smulders et al (2016) found a utility difference of between 252 
0.02 and 0.04 depending on the measurement instrument used after randomizing patients to 253 
unilateral or bilateral implantation. The utility increment associated with bilateral CI over 254 
unilateral CI from Summerfield et al. (2002, 2006) was used (0.031) both because it was 255 
observed using the HUI3, the same instrument used in the current study to estimate the 256 
increment from bimodal stimulation, because it was found consistently across two studies using 257 
contrasting estimation methods, and because it approximated the average value reported across 258 
all four studies. The final utility weights are shown in Table 2. 259 
Resource Use 260 
Direct costs of the hearing aid and the cochlear implant were calculated using the most suitable 261 
and up-to-date unit costs (Table 3). The costs related to unilateral CI were obtained from 262 
published literature (United Kingdom CI Study Group 2004; Bond et al. 2009) and were 263 
inflated using the appropriate inflation ratio from Hospital and Community Health Services 264 
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(HCHS) index (Curtis & Burns 2015). Warranty information of the cochlear implant is 265 
presented as supplemental material (see Supplemental Digital Content 2). 266 
Compared to unilateral CI, bimodal stimulation was associated with additional costs related to 267 
the contralateral hearing aid. Although a proportion of the cohort of severe to profoundly deaf 268 
adults were assumed to already use HAs before implantation (Fig. 1), the model assumed that 269 
additional appointments were provided to each bimodally-aided patient following implantation 270 
in order to ensure the two devices (CI+HA) were optimized to work together. It was assumed 271 
that there was only one follow-up visit related to the HA given that these patients were not new 272 
HA users. It was assumed that the HAs were replaced every 5 years (Bond et al. 2009; 273 
Summerfield et al. 2010; Goman 2014). The costs related to the hearing aids were based on the 274 
UK NHS reference costs 2015/2016 (Department of Health and Social Care, 2016).  275 
In the US analysis, the costs for the hearing aids were gathered from Wertz et al. (2017) and 276 
for the cochlear implantation from Semenov et al. (2013). Costs were inflated to 2017 levels 277 
using the Consumer Price Index (CPI) for the Medical Care system. These parameters are 278 
presented in the supplemental material (see Supplemental Digital Content 3, which 279 
demonstrates the costs used in the US analysis).  280 
Decision making 281 
The final decision of an economic analysis can be presented in the form of Incremental Cost-282 
Effectiveness Ratios (ICERs) or using the Net Monetary Benefit (NMB) approach. The ICER 283 
is defined by the difference in costs between two alternatives divided by the difference in their 284 
health effect. The cost-effectiveness decision is whether this ratio between the incremental 285 
costs and benefits (also referred to as the ‘cost per QALY’) is below the willingness-to-pay 286 
threshold. 287 
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Under the NMB method, the health benefits produced by the interventions under consideration 288 
are expressed in monetary terms using the threshold, and the monetary value of the additional 289 
health benefits is compared to the generated additional costs. An intervention is cost-effective 290 
if it generates higher net monetary benefits compared to the net monetary benefits produced by 291 
the other alternatives; i.e. the difference between the NMBs of an intervention and the next best 292 
alternative (the Incremental NMB, INMB) is greater than zero. 293 
Scenario Analysis 294 
In the primary analysis, it was assumed that all bimodal recipients continue wearing the HA 295 
over a lifetime horizon. However, various studies have suggested that a substantial proportion 296 
of bimodal users may cease using their contralateral HA at some point after implantation 297 
(Cowan and Chin-Lenn 2004; Devoncht et al. 2015;  Fielden & Kitterick 2016; Fitzpatrick and 298 
LeBlanc, 2010; Neuman et al. 2017). The scenario analysis used the weighted average of this 299 
proportion across several published studies (see Supplemental Digital Content 4, which 300 
demonstrates the proportion of adult bimodal users that discontinue hearing aid use) and 301 
assumed that 39% of users would cease HA use after five years. 302 
There is also published evidence supporting the use of age-adjusted utilities as the utility of a 303 
normal-hearing person diminishes over time (Bond et al. 2009). Therefore, a secondary 304 
analysis was conducted using age-dependent utilities to prevent the overestimation of quality 305 
of life for which a scaling factor that reduced utilities as a function of age was extracted from 306 
Bond et al. (2009). 307 
Uncertainty 308 
A univariate sensitivity analysis was conducted by varying the value of each parameter over a 309 
plausible range while all other parameters were held constant (Claxton 2008). Each parameter 310 
was varied between the 2.5% and 97.5% percentile values derived using its confidence interval 311 
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or standard error (Tables 1–3). The results were visualised using a tornado plot in which the 312 
effect of varying each parameter on the main output of the model (the INMB value) were 313 
plotted for each parameter. 314 
The overall level of uncertainty in the model was quantified by conducting a Probabilistic 315 
Sensitivity Analysis (PSA) (Claxton et al. 2005). Instead of each parameter being represented 316 
by a single value, each parameter was represented by a probability distribution that expressed 317 
the likely range of values the parameter could take. Parameters that referred to probabilities 318 
were represented by beta distributions (Table 1), and both utilities (Table 2) and costs (Table 319 
3) were represented by gamma distributions1. Monte Carlo Simulation was used to run the 320 
model 3000 times and generate pairs of incremental costs and QALYs for each alternative by 321 
random sampling. The results are presented on a Cost-Effectiveness Acceptability Frontier 322 
(CEAF), a form of graph that illustrates the uncertainty associated with the optimal treatment 323 
(i.e. the treatment with the highest expected NMB) for different values of the willingness-to-324 
pay threshold (Fenwick et al. 2001; Barton et al. 2008).  The PSA was conducted with Visual 325 
Basic for Applications (VBA) in Microsoft Excel 2016. 326 
In addition to capturing overall uncertainty, the results of the PSA can be analysed to assess 327 
the relative effect of each parameter on the total amount of uncertainty. In other words, it is 328 
possible to identify the parameters that explain the most uncertainty (i.e. variance) in the model 329 
outputs (Campbell et al. 2015). Parameters of interest were identified by analysing the output 330 
                                               
1 A challenge with utilities is they are constrained in the interval (-∞, 1] and no distribution fits 
well. This challenge was overcome by transforming the utilities into disutilities (1-Utility), 
which are bounded between [0, +∞) and can be represented by a gamma distribution. 
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of the 3000 simulation runs of the PSA using Analysis of Covariance (ANCOVA) (Briggs et 331 
al. 2006). The ANCOVA analysis was conducted in SPSS Statistics 24. 332 
 333 
Value Of Information (VOI) 334 
When policy makers use the results of an economic analysis to inform their decision making, 335 
they can choose either to approve/reject a new intervention given the current level of 336 
uncertainty around the decision, or alternatively they can choose to wait until further (more 337 
precise) evidence is obtained from additional research (Briggs et al. 2006). Value Of 338 
Information (VOI) analysis quantifies the value that can be gained from resolving uncertainty; 339 
that is, it estimates the value of conducting additional research. The Expected Value of Perfect 340 
Information (EVPI) is calculated and represents the upper bound of the expected per-patient 341 
benefits of further research.  The EVPI can also be estimated at a population level (pop EVPI) 342 
by incorporating information about the size of the relevant patient population. 343 
The size of the patient population was estimated using the prevalence of adults with profound 344 
deafness who are considered likely to access CI services in the UK and US. Figures from the 345 
British Cochlear Implant Group (BCIG) indicate that on average 800 adults have been 346 
implanted unilaterally each year between 2011 and 2017. The VOI analysis assumed that the 347 
total population of adults who are likely to avail of cochlear implantation in the UK is equal to 348 
800 per year over the next 10 years, which after discounting over that period equated to a 349 
population of 6,886 adults. For the US, the number of adults implanted has increased from 350 
41,000 in 2010 (NIH, 2010) to 58,000 in 2012 (NIH, 2016), a growth of 5,667 per year, 351 
resulting in a 10-year discounted population estimate of 48,780. The discounting period of 10 352 
years was chosen as a time horizon over which the benefits of an optimal decision could be 353 
expected to accrue, but not so long as to mean that some of the treatment options or assumptions 354 
in the model may no longer be applicable. 355 
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RESULTS 356 
Base case results are summarized in Table 4. Bimodal stimulation generates an ICER of £1,521 357 
per QALY compared to unilateral cochlear implantation.  This ICER is below the £20,000 358 
threshold adopted by NICE in the UK, suggesting that bimodal stimulation is more cost-359 
effective than unilateral CI. Bilateral CI is deemed not to be cost-effective as it generates an 360 
ICER of £219,900/QALY compared to bimodal stimulation, and is even less cost-effective 361 
when compared to unilateral CI. The economic evaluation looking at costs from a US 362 
perspective arrived at similar results. Bimodal stimulation generates an ICER of $8,192/QALY 363 
over unilateral CI, while bilateral CI is again not cost-effective compared to the other two 364 
alternatives. 365 
Under the Net Monetary Benefit framework, the INMB from bimodal stimulation compared to 366 
unilateral CI was positive for both the UK (£2114) and US ($4784) perspectives, and is 367 
therefore the preferred alternative among the three treatment options considered. For the UK, 368 
the individual QALY gain (+0.11 years) from offering bimodal stimulation compared to 369 
unilateral CI was reached at an additional cost of £174 per person. The accrual of incremental 370 
NMB at a threshold of £20,000 per QALY over a lifetime horizon is shown in Figure 3 (‘base 371 
case’). Bimodal stimulation offers increasingly more benefits throughout the years compared 372 
to unilateral CI use and starts to generate additional monetary benefits over unilateral CI by the 373 
end of the 1st year after cochlear implantation. 374 
The first scenario analysis re-considered the cost-effectiveness of bimodal stimulation 375 
assuming that approximately 39% of bimodal users would discontinue the use of the HA 376 
voluntarily (Fig. 3, ‘Stop being bimodal’). The incremental NMB was smaller than the base 377 
case but still positive (£1511), and still identified bimodal stimulation as the most cost-effective 378 
alternative. Having less bimodal recipients reduced the expected costs by 0.11% and the 379 
amount of QALYs by an even greater extent (drop of 0.53%) compared to the base case. In 380 
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other words, the reduced health benefits gained from having fewer patients aided bimodally 381 
still outweighed the cost savings arising from having fewer contralateral hearing aid users to 382 
support. The same conclusion can be derived from the US analysis. 383 
The second scenario analysis used utilities that diminished over the patient’s lifetime to reflect 384 
aging-related changes in health. Diminishing utilities generated less NMBs making bimodal 385 
stimulation not cost-effective compared to unilateral CI with a negative INMB of -£1392. A 386 
similar pattern is illustrated in the US analysis. While bimodal stimulation does generate 387 
positive incremental net monetary benefits for the first three decades following implantation, 388 
the utility gained from bimodal use is outweighed by the additional costs once the average age 389 
of the cohort reaches 79 (Fig. 3, ‘Diminishing Utilities’). The cost-effectiveness of bimodal 390 
stimulation under diminishing utilities will therefore be dependent on the assumed average age 391 
at implantation (50 years in the current study), the number of years lived following CI surgery 392 
(23 on average in the current study based on the observed average life expectancy in the cohort 393 
of 83 years), and the time horizon adopted for the analysis (a lifetime horizon was adopted 394 
following the approach taken by NICE when formulating guidance on cochlear implants). 395 
The results of the univariate sensitivity analyses are presented in the left panels of Figure 4. 396 
The key parameters shown in the tornado plot were identified using ANCOVA, which 397 
indicated that the utility parameters had the highest impact on the variance of the model outputs, 398 
contributing to 84% (98% for US) of the overall uncertainty in the INMB. The uncertainty in 399 
the bimodal utility explained 54% (64% for US) of the variance in INMB. A drop in the 400 
bimodal utility of more than 0.029 (0.027 for US) would lead to a negative incremental NMB, 401 
making unilateral cochlear implantation more cost-effective than bimodal stimulation. On the 402 
other hand, a small increase in the bimodal utility resulted in high incremental NMBs; e.g. an 403 
increase of only 6% in the bimodal utility doubled the incremental NMB. Bilateral CI is not 404 
cost-effective compared to either bimodal stimulation and unilateral CI even when using the 405 
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highest reported utility value (an increment of 0.04 compared to unilateral CI) (Smulders et al, 406 
2016). 407 
The model outputs were insensitive to the cost of the acoustic hearing aid in both countries. 408 
Similarly, the appointment costs related to hearing aids (assessment, fitting & follow-up) did 409 
not influence the economic outputs to the extent needed to affect the conclusions of the base 410 
case analysis (Fig. 4, left panels). The univariate sensitivity analysis suggested that the cost 411 
parameters in the US analysis were slightly more influential than the UK analysis, although the 412 
cost-effectiveness of bimodal stimulation remained robust; i.e. no plausible value examined for 413 
the costs related to hearing aids resulted in negative INMB values. The INMB remained 414 
positive for HA device prices up to $6,000. Another influential parameter was the proportion 415 
of patients receiving bimodal stimulation, which explained 13% and 27% of the output variance 416 
in the UK and US analysis, respectively. The relationship between bimodal use and NMB was 417 
positive such that increasing the proportion of bimodally-aided patients resulted in a higher 418 
INMB in both analyses (UK & US). A rise in the number of bimodal users led to greater 419 
increases in health benefits than in costs.  420 
The right panels of Figure 4 also demonstrates the differences in QALYs and costs from the 421 
PSA on a cost-effectiveness plane (scatter plot). Overall, there was little decision uncertainty 422 
surrounding the optimal strategy; the majority of simulation runs were gathered around a tight 423 
cluster below the threshold (i.e. produced a positive INMB) offering robustness to the base 424 
case results. In the UK analysis, the simulations spread more horizontally (across the 425 
incremental QALYs axis), while there was little variance in the incremental costs. This pattern 426 
is compatible with the results of the univariate sensitivity analysis that identified the utility 427 
weights as the key parameters causing uncertainty in the model. In the US analysis, cost 428 
parameters have a bigger role in the overall uncertainty and thus the simulations show a greater 429 
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degree of spread vertically along the incremental cost axis, reflecting the plausible ranges of 430 
costs obtained from the published literature. 431 
Figure 5 plots the Cost-Effectiveness Acceptability Frontier (CEAF) that illustrates both the 432 
optimal decision (the treatment alternative that generates the highest net monetary benefits), 433 
the probability of the decision being correct (the amount of uncertainty around the decision), 434 
and the population-level EVPI (the value of conducting further research) as a function of 435 
willingness-to-pay threshold. The CEAF shows that bimodal stimulation has a high probability 436 
of being cost-effective (p»0.7) across most thresholds compared to the other two alternatives. 437 
For willingness-to-pay thresholds of £20,000/QALY and £30,000/QALY the probability of 438 
bimodal stimulation being the most cost-effective alternative was 72% and 73%, respectively. 439 
In the US analysis, bimodal stimulation was cost-effective with a 67% and 59% certainty at a 440 
$50,000/QALY and $100,000/QALY threshold, respectively (Table 4).  441 
Figure 5 also shows that the EVPI in the UK analysis reached an initial peak where uncertainty 442 
between unilateral CI and bimodal was the highest; i.e. around the threshold value of 443 
£1,900/QALY. The continuous increase in the population EVPI at thresholds above that point 444 
indicates that there is more decision uncertainty around higher thresholds, mostly likely 445 
because the probability of bilateral CI becoming cost-effective increases. At a £20,000/QALY 446 
threshold ($50,000/QALY in the US analysis), the estimated value of reducing uncertainty 447 
through further research is £637 ($1783 in the US) per patient, leading to a population EVPI 448 
estimate of £4,383,922 ($86,955,460 in the US). 449 
  450 
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DISCUSSION 451 
This economic evaluation found that bimodal stimulation is more cost-effective than unilateral 452 
or bilateral cochlear implantation for adults with bilateral severe to profound sensorineural 453 
deafness in both the UK and the US from a public health service perspective. With an ICER of 454 
£1,521/QALY over unilateral CI, bimodal stimulation would be considered highly cost-455 
effective as it is well below the lowest limit of the cost-effectiveness threshold range adopted 456 
by NICE (£20,000/QALY). Similar results are derived from the US analysis, where bimodal 457 
use generated an ICER of $8,192 compared to unilateral CI, well below the $50,000/QALY 458 
threshold. Bimodal stimulation generated greater health benefits than unilateral cochlear 459 
implantation, and on average those benefits outweighed the extra cost burden related to the 460 
maintaining of the contralateral acoustic hearing aids. Although bilateral CI produces more 461 
health benefits (QALYs) than the other treatment alternatives, the excessive costs associated 462 
with providing two cochlear implants means that it is highly unlikely to be the most cost-463 
effective alternative. 464 
The decision on the cost-effectiveness of bimodal stimulation is not sensitive to the choice of 465 
WTP threshold as it is only at thresholds lower than £1,900/QALY that costs of the additional 466 
hearing aids outweigh the benefits they provide to adult CI users. The robustness of the UK 467 
model output is demonstrated by the high level of decision certainty after accounting for the 468 
joint uncertainty in all parameters; i.e. bimodal stimulation was the most cost-effective 469 
alternative in 72% of the model runs at a threshold of £20,000/QALY. An examination of the 470 
proportion of simulations (28%) for which bimodal stimulation was not the most cost-effective 471 
option (in which unilateral CI was more cost-effective) indicated that those results were mainly 472 
driven by bimodal stimulation generating less health than unilateral CI. This situation is not 473 
implausible as there have been reports of poorer outcomes due to interference between 474 
electrical and acoustic inputs and the perceptual differences between the two inputs (Scherf & 475 
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Arnold 2014; Yehudai et al. 2013). This possibility was incorporated in the model by adjusting 476 
the standard errors of the two utility parameters in such a way as to allow for the possibility 477 
that bimodal stimulation could generate less health benefits than unilateral CI use. If improving 478 
the fitting of both hearing devices in bimodal stimulation decreased the possibility of a 479 
reduction in health benefits compared to unilateral CI, decision uncertainty would be reduced 480 
even further, although even without such assumptions decision uncertainty with current 481 
information is low. 482 
The only previous study that has considered the cost-effectiveness of bimodal stimulation 483 
estimated that a utility gain of at least 0.0109 was required to make bimodal stimulation cost-484 
effective. The current study obtained HUI3 data from 91 adults managed at two large CI 485 
services in the UK and estimated a utility gain of 0.032 by comparing a bimodally-aided group 486 
with a unilateral CI group while controlling for years of experience with CI use (Table 2, 487 
unilateral 0.478 vs bimodal 0.510). The size of this utility gain was sufficient to outweigh the 488 
extra costs of maintaining the contralateral HAs if utilities did not diminish over time, and even 489 
if it was assumed a proportion of patients stopped using their contralateral HAs. When utilities 490 
diminished over time under the assumption of an age-related decline in health, bimodal 491 
stimulation only ceased being cost-effective after the patients reached ~80 years of age; i.e. 492 
after approximately 30 years of device use. Thus, even under the assumption that utilities 493 
diminish with age, bimodally-aided adults will get benefit well into their working life. The 494 
basic implication from the age-adjusted utilities analysis is that as patients get to an advanced 495 
age their health looks increasingly similar regardless of the hearing devices they use; i.e. 496 
unilateral CI or CI+HA. 497 
The utility gain for bimodal stimulation used in the present analysis was obtained from UK 498 
patients who had received no rehabilitation specific to bimodal stimulation as it is not routinely 499 
provided in the UK (Fielden & Kitterick 2016). This fact underpinned the assumption that the 500 
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only additional costs for bimodal stimulation associated with that utility gain were the costs 501 
required to ensure the hearing aid was up to date and maintained over time, which is also in 502 
line with the assumptions made by Bond et al. (2009). Even if we used higher cost estimates 503 
as Goman (2014) reported, who assumed a greater level of extra rehabilitation and aftercare in 504 
the bimodal group, the final decision on the cost-effectiveness of bimodal stimulation remains 505 
the same. The overall costs for bimodal stimulation were also higher in the US vs the UK model 506 
in the present evaluation, resulting in an additional cost of $937 per person for bimodal users, 507 
but bimodal stimulation still remained cost-effective. Thus, the current results suggest that 508 
bimodal stimulation would be affordable under a public healthcare system in the US. The 509 
provision of bimodal stimulation in the US not only has the potential to increase patient benefit, 510 
but also reduce inequalities within the healthcare system as contralateral acoustic HAs are not 511 
provided through the public health system in the US, but instead are purchased privately.  512 
Bainbridge and Ramachandran (2014) reported that the prevalence of hearing aid use among 513 
older adults was 28% to 66% higher in those with higher incomes compared to the adults on 514 
the lower end of the income-to-poverty distribution. It is possible that similar differences could 515 
arise in contralateral HA use among adult CI users in the US.  516 
The EVPI depicts the upper price that a healthcare system should be willing to spend for 517 
obtaining additional evidence. Performing more trials and conducting further research provides 518 
more accuracy around the input parameters and resolves part of the uncertainty around the final 519 
outcome of the model. It would appear feasible for randomised controlled trials or other types 520 
of formal clinical evaluations to be conducted within these funding limits (£4,383,922 at 521 
£20,000/QALY; $86,955,460 at $50,000/QALY). If there is scope for further investment, it 522 
should be where the uncertainty is highest.  Results from the sensitivity analyses suggest utility 523 
weights as the key driver of parameter uncertainty. Future research could address this issue by 524 
conducting interventional designs (e.g. randomized controlled trials) to obtain utility weights 525 
for bimodal stimulation compared to unilateral CI, rather than rely on data from observational 526 
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studies on which the current utility weights are based. The lack of health utility data in the field 527 
of cochlear implantation in general is an important evidence gap to address given the important 528 
role that economic evaluations play in determining whether such a low-volume high-cost 529 
intervention is good value for money from the payer’s perspective. 530 
Economic evaluations typically use generic health instruments to obtain data on health-related 531 
quality of life; that is, instruments that are by design relevant to a wide range of health 532 
conditions. Although the EQ-5D (Brooks, 1996; The Euroqol Group, 1990) and Health Utilities 533 
Index Mark 3 (HUI3) (Boyle et al. 1995; Feeny et al. 2002) are both standardized instruments 534 
used in a wide range of health conditions, both are limited in detecting differences between 535 
degrees of hearing loss and changes due to hearing-related interventions. The EQ-5D has been 536 
found to perform poorly in hearing-related conditions in terms of its sensitivity to change 537 
(Barton et al. 2005; Grutters et al. 2007; Longworth et al. 2014). The HUI3 has been found to 538 
be more sensitive although largely to the comparison between ‘no hearing’ to ‘some hearing’ 539 
rather than to different degrees of hearing (or to bilateral versus unilateral hearing) (Lovett et 540 
al. 2009; Goman 2014). Although the EQ-5D is the preferred instrument of NICE (NICE, 541 
2013), it has accepted evidence of the effectiveness of cochlear implantation based on HUI3 542 
data when forming its guidance on who should be able to access cochlear implantation in the 543 
UK (NICE, 2009). This fact and the availability of HUI3 data on the utility gain from bilateral 544 
implantation led to the use of the HUI3 in the current study. However, it is possible that this 545 
choice of instrument was suboptimal given that it’s dimensions do not explicitly cover aspects 546 
of hearing that are contingent on binaural hearing (or at least bilateral access to sound). The 547 
lack of well-validated preference-based measures of health-related quality of life that are 548 
sensitive to hearing and hearing-related interventions but also whose use is suitable for 549 
informing economic evaluations poses an ongoing challenge for the application of health 550 
economics to hearing healthcare. 551 
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The scenario analyses indicated that the incremental net monetary benefits from bimodal 552 
stimulation compared to unilateral CI were reduced substantially if it was assumed that a 553 
proportion of bimodally-aided patients ceased use of their HA after a period of time. Scherf 554 
and Arnold (2014) reported that the main reason for rejecting the hearing aid was the absence 555 
of any perceived benefits. Poor provision and management of bimodal stimulation could 556 
potentially lead to bad synchronisation and malfunctioning of the two devices, reduce benefit, 557 
and ultimately lead to non-use. Differences have been observed across clinical practices in the 558 
procedures used to fit and tune the HA after implantation (Scherf & Arnold 2014) and a 559 
majority of practices in the UK do not have an agreed protocol on the best approach of fitting 560 
both devices simultaneously (Fielden & Kitterick 2016). Surveys of cochlear implant 561 
audiologists have suggested that clinicians need guidelines around issues of bimodal candidacy 562 
and management (Scherf & Arnold 2014; Siburt & Holmes 2015; Fielden & Kitterick, 2016). 563 
Such guidelines could help reduce non-use of the HA by optimizing bimodal fitting procedures 564 
to maximise patient benefit or by ensuring that only patients likely to benefit are aided 565 
bimodally. 566 
The current economic model suggests that a higher number of bimodal users as a proportion of 567 
all CI recipients would lead to even greater net benefits. An increase in bimodal usage in the 568 
UK of approximately 34% that occurred around 2009 has been attributed to the change in 569 
guidance on candidacy criteria in the UK that permitted candidates to have greater access to 570 
residual hearing (Fielden et al. 2016a). Bimodal usage could increase further if the candidacy 571 
criteria for cochlear implantation are expanded to those with even greater levels of residual 572 
hearing. Such an eventuality would seem possible as the candidacy criteria adopted in UK are 573 
some of the most restrictive in the world (Vickers et al. 2016). In the US, providing HAs 574 
through the public healthcare system might increase the rate of contralateral HA use among CI 575 
users without bimodal stimulation necessarily being offered as a distinct treatment option. 576 
Although any increase in bimodal usage would render bimodal stimulation even more cost-577 
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effective than it currently appears to be, it would necessitate audiologists having to manage an 578 
even greater number of bimodally-aided patients in the future. This growing trend places 579 
additional emphasis on the need to develop guidance around maintaining both devices 580 
simultaneously, to develop enhanced fitting procedures, and to identify which patients have the 581 
capacity to derive benefit from a contralateral HA.  582 
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FIGURE CAPTIONS 757 
Figure 1. The decision tree and Markov models used for evaluating costs and health-related 758 
outcomes of combining electric and contralateral acoustic stimulation (CI+HA, ‘Bimodal 759 
stimulation’) compared to electric stimulation alone (unilateral and bilateral CI).  760 
Figure 2. Schematic representation of the Markov Model for use of one or two CIs. Ellipses 761 
indicate distinct health states and arrows show the permitted directions in which the simulated 762 
cohort could move from one state to another. The states reflect the possible post-operative 763 
outcomes following unilateral or bilateral cochlear implantation and two absorbent states of 764 
non-use and death due to natural causes. 765 
Figure 3. Base-case and scenario analysis results of the comparison between bimodal 766 
stimulation and unilateral CI at a willingness-to-pay threshold of £20,000/QALY. Results from 767 
the US analysis are not displayed because they are similar to the UK analysis. 768 
Figure 4. Tornado plots (left) of the one-way sensitivity analyses of bimodal stimulation versus 769 
unilateral CI for the UK (top) and US (bottom) summarizing the uncertainty attached to each 770 
individual parameter. Key parameters were identified using analysis of covariance. Each 771 
parameter was varied between the 2.5% and 97.5% percentile. Scatter plots (right) of 772 
incremental costs and incremental quality-adjusted life years of bimodal stimulation versus 773 
unilateral CI. The majority of simulation runs (UK 72%; US 67%) were observed to lie below 774 
the willingness-to-pay threshold.  775 
Figure 5. Cost-Effectiveness Acceptability Frontier (CEAF) representing the results from the 776 
probabilistic sensitivity analysis. The graph illustrates the management option with the highest 777 
expected net monetary benefits (NMB), the probability that this intervention is cost-effective, 778 
and the population Expected Value of Perfect Information (pop EVPI) across a range of 779 
willingness-to-pay thresholds.  All three treatment alternatives were considered (unilateral CI, 780 
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bimodal stimulation and bilateral CI) although no part of the graph relates to bilateral CI as it 781 
was not the optimal choice at any of the WTP threshold values considered.  Results from the 782 
US analysis are not displayed because they are similar to the UK analyses. 783 
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Table 1.  Probability parameters of the Markov state transition models. The means and standard errors (SEs) were used to 
define beta distributions for the probabilistic sensitivity analyses. 
Parameter Name Mean SE Source Description 
Screening 0.3 0.075 Bond 2009 Proportion of initial referrals not undergoing an 
operation to fit a CI (i.e. who receive non-surgical 
management) 
Bimodal users 0.454   0.1135 
 
 
Fielden 2016, 2017 Proportion of CI recipients who use a contralateral 
HA 
Surgical Death 0 N/A Bond 2009 Probability of death from cochlear implant surgery 
External failure* 0.062 0.0155 Bond 2009 6-month probability of external component (sound 
processor) failure 
Internal failure* Time-
dependent 
N/A Cochlear Europe 
submission, Conboy 
and Gibbin 2004 
6-month probability of internal component (receiver-
stimulator & electrode array) failure 
Major complications yr 1* 0.02 0.005 Bond 2009 6-month probability of major complication† in year 1   
Major complications yr 2+* 0.002 0.0005 Bond 2009 6-month probability of major complication† in year 
2+ 
CI extraction 0.115 0.0049 Bond 2009 Probability of non-reimplantation of a cochlear 
implant due to internal failure or major complications 
Elective non-use of CI 0.0236 0.0059 Bond 2009 Probability of voluntary non-use of implants (applied 
once at the end of 2nd year of implant use) 
Use of 1 HA 0.25 0.125 Bond 2009 Proportion of candidates for CI who use 1 HA 
Use of 2 HAs 0.25 0.125 Bond 2009 Proportion of candidates for CI who use 2 HAs 
*Probability is doubled for bilateral cochlear implantation. †Event requiring any form of operation not related to a device failure. 
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Table 2. Utility parameters of the Markov state transition models. All utilities were based on data obtained using the 
HUI3 instrument. Lower and Upper 95% Confidence Intervals (LCI, UCI) were calculated by bootstrapping, which was 
also used as the sampling method for these parameters in the probabilistic sensitivity analyses. 
Parameter Name Mean LCI UCI Source Description 
Absolute utilities      
Non-surgical management 0.433 0.411 0.455 Bond 2009 Utility of profoundly deaf adults with 
access to HAs 
Unilateral CI 0.478 0.420 0.536 Current study Utility of unilateral cochlear implant use 
Bimodal 0.510 0.428 0.592 Current study Utility of bimodal use 
      
Incremental utilities      
Bilateral CI 0.031 0.018 0.042 Summerfield 2010 Incremental utility gain from using 
bilateral cochlear implants over a unilateral 
implant 
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Table 3. Cost parameters of the Markov state transition models measured in Pound Sterling (£). The means and Lower 
and Upper 95% Confidence Intervals (LCI, UCI) or standard errors (SEs) were used to define gamma distributions for 
the probabilistic sensitivity analyses. 
Parameter Name Mean  LCI-UCI (SE) Source Description 
Costs of HA       
Hearing Aid 86 65-108 NHS Reference Costs 2015-2016 Cost of a hearing aid 
Assessment 53 40-66 NHS Reference Costs 2015-2016 Cost of a hearing aid assessment 
Fitting 71 53-89 NHS Reference Costs 2015-2016 Cost of fitting a hearing aid 
Follow-up 53 40-67 NHS Reference Costs 2015-2016 Cost of follow-up after hearing 
aid fitting 
Costs of a CI       
Candidacy  4945 3907-5587 Bond 2009* Presurgical candidacy costs 
CI surgery (Unilateral) 3469 1144-7528 Bond 2009* Unilateral implantation costs 
(excluding system costs) 
CI surgery (Bilateral) 5204 (1041†) Bond 2009* Bilateral implantation costs 
(excluding system costs) 
CI device (Unilateral) 14900 (3603†) NICE 2009 Mean cost of unilateral cochlear 
implant system 
CI device (Bilateral) 23840 (4768†) NICE 2009 Mean cost of bilateral cochlear 
implant system, assuming a 40% 
discount for the second implant 
(NICE, 2009) 
Maintenance yr1 
(Unilateral) 
6164 5425-6534 Bond 2009* Tuning and maintenance costs in 
year 1 
Maintenance yr2 984 757-1436 Bond 2009* Maintenance costs in year 2 
Maintenance yr3 932 392-1435 Bond 2009* Maintenance costs in year 3 
Maintenance yr4+ 735 391-1079 Bond 2009* Maintenance costs in years 4+ 
Upgrade (Unilateral) 5072 (101†) Bond 2009* Processor upgrade 
Major Complications 
(Unilateral) 
9588 9004-10519 Bond 2009* Medical event requiring surgery 
not related to device failure 
*Inflated to 2015/16 prices. †Variance of costs set to 1/5 of the mean value following Summerfield et al. (2010). 
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Table 4. Results of the cost-effectiveness analyses for the base case. 
Treatment 
Alternative 
Expected 
QALYS 
Expected 
Costs ICER* NMB INMB* 
Probability of being cost-effective† 
£20,000/QALY £30,000/QALY 
United Kingdom (WTP threshold £20,000/QALY)  
Unilateral CI 5.87 £33,227 - £84,050 - 28% 27% 
Bimodal 5.98 £33,401 £1,521/QALY £86,165 £2,114 72% 73% 
Bilateral CI 6.11 £62,688 £219,900/QALY £59,542 -£26,623 0% 0% 
United States (WTP threshold $50,000/QALY)  $50,000/QALY $100,000/QALY 
Unilateral CI 5.87 $46,229 - $246,964 - 30% 24% 
Bimodal 5.98 $47,166 $8,192/QALY $251,748 $4,784 67% 59% 
Bilateral CI 6.11 $79,120 $239,926/QALY $226,453 -$25,295 3% 17% 
*Incremental values calculated by comparing adjacent rows; i.e. Bimodal aiding to Unilateral CI and Bilateral CI to 
Bimodal aiding. †Probabilities represent the proportion of simulations for which each treatment alternative generated the 
greatest net monetary benefits. 
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APPENDICES 
 
Survival Curves to inform the probability of failure of the internal component of a 
single cochlear implant.
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Table A. Warranty and lifetime parameters for the hearing devices considered in the Markov models. 
Parameter Mean SE Source Description 
Proportions in warranty     
Proportion of internal failures  0.007  Bond 2009 Proportion of internal component failures 
occurring during warranty period 
Proportion of external failures  0.318  Bond 2009 Proportion of external component failures 
occurring during warranty period 
Warranty costs (£)     
Internal Failure (during warranty) 3469 694† Bond 2009* Cost of internal component failure (during 
warranty period) 
Internal Failure (after warranty) 21483 4297† Bond 2009* Cost of internal component failure (in years 
after warranty period) 
External Failure (during warranty) 0 19† Bond 2009* Cost of external component failure (during 
warranty period) 
External Failure (after warranty) 5072 1014† Bond 2009* Cost of external component failure (in years 
after warranty period) 
Lifetime in years     
Lifetime of an HA 5  Bond 2009 
Summerfield 2010  
Goman 2014 
The number of years after which an acoustic 
hearing aid is likely to be upgraded in routine 
clinical practice. 
Warranty of CI (internal) 10  Bond 2009 The warranty period of the internal part of a CI 
Warranty of CI (external) 3  Bond 2009 The warranty period of the external part of a CI 
*Inflated to 2015/16 prices. †Variance of costs set to 1/5 of the mean value following Summerfield et al. (2010). 
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Table B. Cost parameters of the Markov state transition models. Measures in US Dollars ($)*. 
Parameter Name Mean SE† Source Description 
Costs of HA      
Hearing Aid 700 140 Wertz et al. 2017 Cost of a hearing aid 
Assessment 234 47 Wertz et al. 2017 Cost of assessment of a hearing aid 
Fitting 197 39 Wertz et al. 2017 Cost of fitting of a hearing aid 
Follow-up 197 39 Wertz et al. 2017 Cost of follow-up of a hearing aid 
     
Costs of CI     
Candidacy  1650 330 Semenov et al. 2013 Presurgical candidacy costs 
CI surgery (Unilateral) 6010 1202 Semenov et al. 2013 Unilateral implantation costs (excluding system costs) 
CI surgery (Bilateral) 9015 1803 Bond et al. 2009 Bilateral implantation costs (excluding system costs) 
CI (Unilateral) 36162 7232 Semenov et al. 2013 Mean cost of unilateral cochlear implant system 
CI (Bilateral) 57859 11572 Bond et al. 2009 Mean cost of bilateral cochlear implant system, 
assuming a 40% discount for the second implant 
Maintenance yr1-3 1997 399 Semenov et al. 2013 Annual tuning and maintenance costs in year 1-3 
including sound processor insurance 
Maintenance yr4+ 1579 316 Semenov et al. 2013 Maintenance costs in years 4+ including sound 
processor insurance 
Upgrade 2976 595 Semenov et al. 2013 Processor update every 10 years 
Major Complications 6259 1252 Semenov et al. 2013 Cost of major complications (unilateral) 
     
Warranty costs     
Replacement of external 
component 
- - Semenov et al. 2013 Cost of external component replacement is covered by 
insurance 
Replacement of internal 
component (during warranty) 
6010 1202 Semenov et al. 2013 Cost of internal component replacement 
*Inflated to 2017 prices, based on the Consumer Price Index (Bureau of Labor Statistics) 
†Variance of costs set to 1/5 of its mean value following Summerfield et al. (2010). 
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Table C. Estimates of the proportion of adult bimodal users that discontinue hearing aid use. 
Study Proportion of sample stopping HA use (%) Sample size Follow up Source 
Fielden et al. (2016) 59 38 5 years Estimates from CI audiologists, UK 
Neuman et al. (2017) 15 94 3 months Unilateral CI adults, New York 
Devocht et al. (2015) 36 77 1 year Unilateral CI adults, Netherlands 
Yamaguchi et al. (2013) 85 82 Not specified Unilateral CI adults, Brazil 
Fitzpatrick and Leblanc (2010) 51 96 6 months Unilateral CI adults, Canada 
Fitzpatrick et al. (2009) 21 24 6 months Unilateral CI adults, Canada 
Cowan and Chin-Lenn (2004) 21 71 Not specified Unilateral CI adults, Australia 
 
 
